Impact of neutrophil-to-lymphocyte ratio on survival outcomes among cirrhotic and non-cirrhotic patients with advanced hepatocellular carcinoma under atezolizumab–bevacizumab combination therapy
Cirrhotic/NLR-H HCC patients presented the worst survival. NLR is an independent risk factor for worse survival in cirrhotic patients. Prior therapy is the only factor significantly correlated with OS and PFS in non-cirrhotic patients.
Authors
- Spyridon Pantzios (ORCID: https://orcid.org/0000-0003-3038-3084)
Institutions
- Stavros Niarchos Foundation (GR)
Publication Details
- Journal
- Annals of Gastroenterology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.20524/aog.2025.0963
- Citations
- 1
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.35